This message contains images. If you don't see images, click here to view.
Click
here to advertise in this news brief.
|
|
| |
AJCC calls for contributors to Cancer Staging Manual, 8th Edition
American Joint Committee on Cancer
The American Joint Committee on Cancer is seeking cancer professionals to collaborate on the development of the AJCC Cancer Staging Manual, Eighth Edition.
A number of opportunities are available in two areas:
Disease Site Expert Panel: Members will research, write, review or otherwise contribute to chapter content.
Review Core: Members will provide expert review of all content in the areas of evidence-based medicine and statistics, precision medicine, cancer registry and surveillance and data harmonization.
Access the application online. AJCC will not accept unsolicited curriculum vitaes. Only individuals who complete this application will be considered. The application period will close June 30. Contact ajcc@facs.org for more information.
|
|
Share this article:
    |
|
|
Advertisement
Myriad BRCA patents ruled invalid by US Supreme Court
Los Angeles Times
In a highly anticipated decision, the Supreme Court has effectively invalidated the patents held by Myriad Genetics for the BRCA1 and BRCA2 genes. However, the ruling is not all bad news for Myriad. The Court unanimously ruled that although naturally isolated DNA is not patentable, synthetically created exon-only strands of nucleotides — complementary (c)DNA — is patentable.
2 gene variants may predict who will benefit from breast cancer prevention drugs
National Institutes of Health
In women at high risk for breast cancer, a long-term drug treatment can cut the risk of developing the disease in half. Researchers supported by the National Institutes of Health have now identified two gene variants that may predict which women are most likely to benefit from this therapy — and which should avoid it.
PRODUCT SHOWCASE
 |
|
MediGain has analyzed the top physicians offices around the country and compiled the Top 10 Metrics they use to maximize their practice's revenue. You can't manage what you can't measure. Here are 10 metrics that you can track so you can spend more time providing quality health care for your patients. Plus, you will end up with more cash at the end of the day/month/year.
|
|
Cancer researchers find therapeutic potential in 'undruggable' target
Harvard Gazette
Harvard Stem Cell Institute researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal and are beginning a creative search for a drug that can block its activity.
Persistent heartburn sufferers could have oesophageal cancer
The Telegraph
Early symptoms are often dismissed as heartburn, leading to late diagnosis and low survival rates — on average patients live only three months and just 13 percent survive five years or more — according to figures released by Cancer Research UK.
|
FEATURED COMPANIES
Oncology OnTrack is used to navigate patients with any cancer type from screening to diagnosis, treatment and survivorship, interfaces with other programs and supports accreditations.
|
|
To find out how to feature your company in The CoC Brief and other advertising opportunities, contact James DeBois at 469-420-2618.
MORE
|
|
Which women should receive preventive breast cancer drugs?
Medical News Today
A new study, published in the journal Cancer Discovery, revealed that genetic variations could be a key indicator of which women are likely and which are unlikely to benefit from tamoxifen or raloxifene for breast cancer prevention.
| Looking for similar articles? Search here, keyword BREAST CANCER. |
|
Biomarker could predict HPV-related oropharyngeal cancer early on
Genetic Engineering & Biotechnology News
A team led by investigators at the U.S. National Cancer Institute has found that antibodies against human papillomavirus could be useful biomarkers for detecting individuals who are at greatly heightened risk of HPV-related oropharyngeal cancer.
Lists of cancer mutations awash with false positives
Nature
Some call them the "fishy genes." Errors in DNA that seem to be associated with tumors, but which researchers trawling through cancer genome data cannot explain. For instance, why would mutations in genes involved in the sense of smell be linked to lung cancer?
Developmental protein plays role in spread of cancer
National Cancer Institute
A protein used by embryo cells during early development, and recently found in many different types of cancer, apparently serves as a switch regulating the spread of cancer, known as metastasis, report researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center in a recent issue of the journal Cancer Research.
New lung cancer guidelines recommend offering screening to high-risk individuals
Science Codex
In Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, the American College of Chest Physicians, recommends offering low-dose computed tomography scanning for lung cancer screening to people with a significant risk of lung cancer due to age and smoking history.
Scientists uncover clues to cancer's spread
The Telegraph
Experiments carried out by a team at University College London have uncovered clues in what causes the disease to migrate from one part of the body to another. In many cases death is not caused by the primary tumor, but the secondary growth.
Source of tumor growth in aggressive prostate cancer found
Science Codex
Researchers have discovered a molecular switch that explains, at least in part, how some fast-growing prostate cancers become resistant to hormone treatment, a new study conducted in human cell cultures and mice finds. The results were presented at The Endocrine Society's 95th Annual Meeting in San Francisco.
|
|
|
|
|
|
The CoC Brief
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit
Andrew Plock, Content Editor, 469.420.2609
Contribute news
Disclaimer: The CoC Brief is a digest of the most important news selected for the American College of Surgeons Commission on Cancer from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Commission on Cancer does not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons and the Commission on Cancer.
Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.
This edition of The CoC Brief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
|
|
Recent issues
June 12, 2013
June 5, 2013
May 29, 2013
May 22, 2013
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
Mobile version